natgillin/translations-raw huggingface dataset:
What benefits of Simparica Trio have been shown in studies? 
Kakšne koristi zdravila Simparica Trio so se pokazale v študijah?
An overview of Simparica Trio and why it is authorised in the EU 
Pregled zdravila Simparica Trio in zakaj je odobreno v EU
The appropriate tablet strength should be used according to the dog's weight. 
Ustrezna jakost tablete se določi glede na telesno maso psa.
In areas where lungworm and heartworm are present, treatments are required at monthly intervals. 
Na območjih, kjer so prisotne pljučne in srčne gliste, so zdravljenja potrebna v enomesečnih intervalih.
What is Simparica Trio and what is it used for? 
Kaj je zdravilo Simparica Trio in za kaj se uporablja?
It blocks the normal movement of charged chloride particles (ions) in and out of nerve cells, especially those associated with gamma-aminobutyric acid (GABA) and glutamate, two substances that convey signals between nerves (neurotransmitters). 
Zavira normalno prehajanje nabitih kloridnih delcev (ionov) v živčne celice in iz njih, in sicer zlasti tistih, ki so povezani z gamaaminomasleno kislino (GABA) in glutamatom, tj. dvema snovema, ki prenašata signale med živci (živčna prenašalca).
What are the risks associated with Simparica Trio? 
Kakšna tveganja so povezana z zdravilom Simparica Trio?
This means that it kills parasites present on the skin or in the fur of animals, such as fleas and ticks. 
To pomeni, da uniči parazite na koži ali v dlaki živali, kot so bolhe in klopi.
It acts by blocking signals, normally associated with the neurotransmitter acetylcholine, from their nerves to their muscles, causing sudden contraction followed by paralysis and death. 
Deluje tako, da zavira signale, ki so običajno povezani z živčnim prenašalcem acetilholinom in ki potujejo od živcev do mišic, s čimer povzroči nenadno krčenje, ki mu sledita paraliza in smrt.
For the list of restrictions, see the package leaflet. 
Znanih neželenih učinkov ni. Za celoten seznam omejitev glejte navodilo za uporabo.
Roundworms and hookworms 
Valjasti in kavljasti črvi
Moxidectin causes paralysis and death of these parasites by interfering in a different way to sarolaner with the flow of chloride ions in nerve cells associated with GABA and glutamate. 
Moksidektin povzroči paralizo in pogin teh parazitov tako, da na drugačen način kot sarolaner onemogoči pretok kloridnih ionov v živčnih celicah, povezanih z GABA in glutamatom.
The study showed Simparica Trio to be comparable to the comparator medicine as measured by the percentage reduction in live tick counts on day 7, 14, 21 and 30 after treatment. 
Študija je pokazala, da je zdravilo Simparica Trio primerljivo s primerjalnim zdravilom, merjeno z odstotkom zmanjšanja števila živih klopov na 7., 14., 21. in 30. dan po zdravljenju.
In a field study involving 622 dogs in an area of Denmark and Italy known to be affected by lungworm disease, dogs treated with Simparica Trio every 30 days until day 270 did not test positive for lungworm until day 300 after first treatment and therefore the effectiveness was 100% with some dogs testing positive in the control group which was given a dummy treatment. 
V terenski študiji, v katero je bilo vključenih 622 psov na Danskem in v Italiji, za katere je bilo znano, da so bili infestirani s pljučnimi glistami, so bili psi, ki so bili vsakih 30 dni do 270. dne zdravljeni z zdravilom Simparica Trio, do 300. dne po prvem zdravljenju negativni na prisotnost pljučnih glist, zaradi česar se učinkovitost tega zdravila šteje za 100 %, medtem ko bili nekateri psi v kontrolni skupini, zdravljeni s placebom, pri testiranju pozitivni.
Pyrantel also kills roundworms and hookworms present in the gut but acts differently to moxidectin. 
Pirantel prav tako uniči valjaste in kavljaste črve v črevesju, vendar na drugačen način kot moksidektin.
For flea or tick infestations, one treatment with Simparica Trio is effective for up to 5 weeks. 
Za zdravljenje infestacij z bolhami ali klopi zadostuje eno zdravljenje z zdravilom Simparica Trio, ki učinkuje do pet tednov.
For gut worms only a single treatment is required. 
Pri črevesnih črvih je potrebno samo eno zdravljenje.
Further flea or tick treatment should be continued using a different veterinary medicine with a narrower range of action. 
Za nadaljnje zdravljenje infestacij z bolhami ali klopi je treba uporabiti druga zdravila za uporabo v veterinarski medicini z ožjim spektrom delovanja.
For more information about using Simparica Trio, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Simparica Trio glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
In a US study of 410 dogs in an area affected by heartworm disease, dogs treated with Simparica Trio every 30 days until day 300 showed 100% effectiveness based on blood tests at days 120, 240 and 330 after first treatment. 
V ameriški študiji s 410 psi z območja, kjer razsajajo srčne gliste, so bili psi, ki so bili vsakih 30 dni do 300. dne zdravljeni z zdravilom Simparica Trio, so na podlagi krvnih preiskav na 120., 240. in 330. dan po prvem zdravljenju potrdili 100 % učinkovitost zdravila.
Simparica Trio is a veterinary medicine used to treat dogs with flea or tick infestations and roundworm or hookworm infections in the gut. 
Simparica Trio je zdravilo za uporabo v veterinarski medicini, ki se uporablja pri psih za zdravljenje infestacij z bolhami ali klopi ter okužb z valjastimi ali kavljastimi črvi.
Safety information has been included in the summary of product characteristics and the package leaflet for Simparica Trio, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. 
V povzetek glavnih značilnosti zdravila Simparica Trio in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
Fleas 
Bolhe
Effectiveness, based on faecal egg counts on day 7 after treatment, for dogs treated with Simparica Trio was comparable to the comparator medicine. 
Učinkovitost zdravljenja, ki je bila izmerjena s številom jajčec v blatu na sedmi dan po zdravljenju, je bila pri psih, ki so bili zdravljeni z zdravilom Simparica Trio, primerljiva s primerjalnim zdravilom.
At the same time, Simparica Trio is used to prevent heartworm and lungworm disease (both caused by blood worms that infect the heart and blood vessels supplying the lungs). 
Prav tako se uporablja za preprečevanje obolenj, ki jih povzročajo srčne in pljučne gliste (gliste v krvi, ki se naselijo v srcu in žilah, ki oskrbujejo pljuča).
Simparica Trio must only be used when there is a need to treat both fleas or ticks and worms in the gut. 
Zdravilo Simparica Trio se lahko uporablja le, kadar je treba istočasno zdraviti bolhe ali klope in črevesne črve.
Simparica Trio is available as chewable tablets and can only be obtained with a prescription. 
Zdravilo Simparica Trio je na voljo v obliki žvečljivih tablet, predpisovanje in izdaja zdravila pa je le na recept.
The study showed Simparica Trio to be comparable to the comparator medicine as measured by flea counts on day 14 and 30 after treatment. 
Študija je pokazala, da je zdravilo Simparica Trio primerljivo s primerjalnim zdravilom, merjeno s številom bolh na 14. in 30. dan po zdravljenju.
Simparica Trio received a marketing authorisation valid throughout the EU on 17 September 2019. 
Zdravilo Simparica Trio je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, dne
Heartworms 
Klopi
In a field study in dogs infested with at least 5 live fleas, 297 dogs were treated with Simparica Trio and 164 dogs with afoxolaner and milbemycin oxime (an authorised treatment for fleas and ticks). 
V terenski študiji pri psih, ki so bili infestirani z vsaj petimi živimi bolhami, je bilo 297 psov zdravljenih z zdravilom Simparica Trio, 164 psov pa z afoksolanerjem in milbemicin oksimom (odobrenima zdraviloma proti bolham in klopom).
How does Simparica Trio work? 
Kako zdravilo Simparica Trio deluje?
In a field study involving dogs infected with roundworms or hookworms, 194 dogs were treated with Simparica Trio and 97 dogs with afoxolaner and milbemycin oxime. 
V terenski študiji pri psih, ki so bili infestirani z valjastimi ali kavljastimi črvi, je bilo 194 psov zdravljenih z zdravilom Simparica Trio, 97 psov pa z afoksolanerjem in milbemicin oksimom.
In a further field study in dogs infested with at least 3 live ticks, 189 dogs were treated with Simparica Trio and 91 dogs with afoxolaner and milbemycin oxime. 
V dodatni terenski študiji pri psih, ki so bili infestirani z vsaj tremi živimi klopi, je bilo 189 psov zdravljenih z zdravilom Simparica Trio, 91 psov pa z afoksolanerjem in milbemicin oksimom.
Moxidectin kills parasites present inside the body of animals, such as roundworms, hookworms, lungworm and heartworm. 
Moksidektin uniči parazite v telesu živali, kot so valjasti in kavljasti črvi ter pljučne in srčne gliste.
Simparica Trio contains the active substances sarolaner, moxidectin and pyrantel. 
Zdravilo Simparica Trio vsebuje učinkovine sarolaner, moksidektin in pirantel.
How is Simparica Trio used? 
Kako se zdravilo Simparica Trio uporablja?
Simparica contains three active substances: sarolaner, moxidectin and pyrantel. 
Zdravilo Simparica Trio vsebuje tri učinkovine: sarolaner, moksidektin in pirantel.
Lungworms 
Pljučne gliste
EPAR summary for the public telmisartan 
Povzetek EPAR za javnost telmisartan
Page 2/2 
Če želena vrednost krvnega stran 2/2
It is available as white tablets (round: 20 mg; oval: 40 mg; capsule-shaped: 80 mg). 
Na voljo je v obliki belih tablet (okroglih: 20 mg; ovalnih: 40 mg; v obliki kapsule: 80 mg).
Other information about Tolura: 
Druge informacije o zdravilu Tolura:
The European Commission granted a marketing authorisation valid throughout the EU for Tolura to Krka, d.d., Novo mesto on 4 June 2010. 
Evropska komisija je dovoljenje za promet z zdravilom Tolura, veljavno po vsej Evropski uniji, odobrila družbi Krka, d.d., Novo mesto, dne 4. junija 2010.
It is used in patients who have had problems due to blood clots in the past (such as heart disease or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys). 
Uporablja se pri bolnikih, ki so imeli težave zaradi krvnih strdkov v preteklosti (kot so srčno obolenje, možganska kap ali arterijska bolezen) ali ki imajo sladkorno bolezen tipa 2, ki je poškodovala določen organ (npr. oči, srce ali ledvice).
Tolura is used to treat essential hypertension (high blood pressure) in adults. 
Zdravilo Tolura se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
This document is a summary of the European Public Assessment Report (EPAR) for Tolura. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Tolura.
This means that Tolura is similar to a ‘reference medicine' already authorised in the European Union (EU) called Micardis. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Micardis.
For more information about treatment with Tolura, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Tolura preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
What are the benefit and risk of Tolura? 
Kakšne so koristi in tveganja, povezani z zdravilom Tolura?
The doctor should monitor the patient's blood pressure closely when starting Tolura, and may decide to adjust the patient's blood pressure-lowering medication. 
Zdravnik mora skrbno spremljati bolnikov krvni tlak ob začetku zdravljenja z zdravilom Tolura in se lahko odloči za prilagoditev zdravila za zniževanje bolnikovega krvnega tlaka.
The full EPAR for Tolura can be found on the Agency's website: EMA website/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Tolura je na voljo na spletni strani agencije: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tolura. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Tolura, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The Committee recommended that Tolura be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Tolura odobri dovoljenje za promet.
Because Tolura is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's. 
Ker je zdravilo Tolura generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Tolura is a ‘generic medicine'. 
Zdravilo Tolura je „generično zdravilo“.
Tolura is a medicine that contains the active substance telmisartan. 
Tolura je zdravilo, ki vsebuje zdravilno učinkovino telmisartan.
For the treatment of essential hypertension, the recommended dose of Tolura is 40 mg once a day, but some patients may benefit from using a 20-mg dose. 
Za zdravljenje esencialne hipertenzije znaša priporočeni odmerek zdravila Tolura 40 mg enkrat dnevno, toda za nekatere bolnike zadostuje že 20-miligramski odmerek.
The active substance in Tolura, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. 
Zdravilna učinkovina v zdravilu Tolura, telmisartan, je „antagonist receptorjev angiotenzina II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide. 
tlaka ni dosežena, se lahko odmerek poveča na 80 mg ali pa se doda drugo zdravilo za zdravljenje povišanega krvnega tlaka, kot je hidroklorotiazid.
Therefore, the CHMP's view was that, as for Micardis, the benefit outweighs the identified risk. 
Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Micardis, odtehtajo znana tveganja.
This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack. 
Zaradi tega se krvni tlak zniža, kar posledično zmanjša tveganja, povezana s previsokim krvnim tlakom, kot sta na primer srčni napad ali možganska kap.
Tolura is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks. 
Zdravilo Tolura se uporablja tudi za preprečevanje kardiovaskularnih težav (težav s srcem in krvnimi žilami), kot sta srčni infarkt ali možganska kap.
Because Tolura is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis. 
Ker je zdravilo Tolura generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Micardis.
The CHMP concluded that, in accordance with EU requirements, Tolura has been shown to have comparable quality and to be bioequivalent to Micardis. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Tolura primerljivo raven kakovosti kot zdravilo Micardis ter da mu je biološko enakovredno.
Why has Tolura been approved? 
Zakaj je bilo zdravilo Tolura odobreno?
How has Tolura been studied? 
Kako je bilo zdravilo Tolura raziskano?
What is Tolura used for? 
Za kaj se zdravilo Tolura uporablja?
How does Tolura work? 
Kako zdravilo Tolura deluje?
What is Tolura? 
Kaj je zdravilo Tolura?
How is Tolura used? 
Kako se zdravilo Tolura uporablja?
Around 99% of patients with genotype 1 infection (125 out of 126), 96% of patients with genotype 2 infection (25 out of 26) and 89% of patients with genotype 3 infection (16 out of 18) did not show any sign of the virus in their blood 12 weeks after the end of their planned treatment. 
Pri približno 99 % bolnikov, okuženih z genotipom 1 (125 od 126), 96 % bolnikov, okuženih z genotipom 2 (25 od 26), in 89 % bolnikov, okuženih z genotipom 3 (16 od 18), 12 tednov po koncu načrtovanega zdravljenja niso odkrili nobenih znakov virusa v krvi.
The usual dose is 60 mg once a day for 12 or 24 weeks. 
Običajni odmerek je 60 mg enkrat na dan, tablete pa je treba jemati dvanajst ali 24 tednov.
This is a summary of the European public assessment report (EPAR) for Daklinza. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Daklinza.
The full EPAR and risk management plan summary for Daklinza can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Daklinza sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The patients in the study were infected with genotypes 1, 2 or 3 and all received treatment for 12 or 24 weeks. 
Bolniki v študiji so bili okuženi z genotipom 1, 2 ali 3 in so zdravljenje prejemali 12 ali 24 tednov.
Daklinza is available as 30, 60, and 90 mg tablets. 
Zdravilo Daklinza je na voljo v obliki 30, 60 in 90-miligramskih tablet.
The dose may have to be raised or lowered if the patient is taking other medicines that decrease or increase Daklinza's effects. 
Odmerek se lahko poveča ali zmanjša, če bolnik jemlje druga zdravila, ki povečujejo ali zmanjšujejo učinke zdravila Daklinza.
What is Daklinza and what is it used for? 
Kaj je zdravilo Daklinza in za kaj se uporablja?
What benefits of Daklinza have been shown in studies? 
Kakšne koristi je zdravilo Daklinza izkazalo v študijah?
What are the risks associated with Daklinza? 
Kakšna tveganja so povezana z zdravilom Daklinza?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Daklinza have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Daklinza upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in
By blocking this protein, the medicine stops the hepatitis C virus from multiplying. 
Z zaviranjem te beljakovine zdravilo prepreči razmnoževanje virusa hepatitisa C.
This study is being carried out in light of data suggesting that patients treated with these medicines who have had liver cancer could be at risk of their cancer returning early. 
Ta študija se izvaja na podlagi podatkov, ki kažejo, da pri bolnikih, ki se zdravijo s temi zdravili in so preboleli raka jeter, obstaja tveganje njegove zgodnje ponovitve.
For more information about treatment with Daklinza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Daklinza preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali
Daklinza must be used in combination with other medicines for chronic hepatitis C, such as sofosbuvir, peginterferon alfa and ribavirin. 
Zdravilo Daklinza je treba uporabljati v kombinaciji z drugimi zdravili za zdravljenje kroničnega hepatitisa C, na primer s sofosbuvirjem, peginterferonom alfa in ribavirinom.
Several varieties (genotypes) of hepatitis C virus exist and Daklinza is recommended for use in patients with virus of genotypes 1, 3 and 4. 
Obstaja več vrst (genotipov) virusa hepatitisa C, zdravilo Daklinza pa je priporočeno za bolnike z virusom genotipa 1, 3 in 4.
Daklinza must not be used together with certain medicines that may reduce the effects of Daklinza. 
Zdravilo Daklinza se ne sme uporabljati sočasno z določenimi zdravili, ki lahko zmanjšajo njegove učinke.
Additional studies involving patients with genotypes 4 indicate that Daklinza is also as effective against genotype 4 as it is against genotype 1. 
Dodatne študije pri bolnikih z genotipom 4, so pokazale, da je zdravilo Daklinza tudi proti genotipu 4 enako učinkovito kot proti genotipu 1.
The European Medicines Agency noted that Daklinza used in combination with other medicines was shown to be effective against hepatitis C virus, including in patients with genotype 1 resistant to previous treatment. 
Evropska agencija za zdravila je ugotovila, da se je zdravilo Daklinza, uporabljeno v kombinaciji z drugimi zdravili, izkazalo za učinkovito proti virusu hepatitisa C, tudi pri bolnikih z genotipom 1, ki je bil odporen proti predhodnemu zdravljenju.
It is not intended to provide practical advice on how to use Daklinza. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Most patients had not previously been treated for hepatitis C, though some had genotype 1 infection that was resistant to standard medicines (consisting of either telaprevir or boceprevir - the so-called NS3/4A inhibitors - in combination with peginterferon alfa and ribavirin). 
Večina bolnikov se pred tem še ni zdravila zaradi okužbe s hepatitisom C, nekateri pa so bili okuženi z genotipom 1, ki je bil odporen proti standardnemu zdravljenju (ki sestoji bodisi iz telaprevirja ali boceprevirja - tako imenovanih zaviralcev NS3/4A - v kombinaciji s
What measures are being taken to ensure the safe and effective use of 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Daklinza?
The most common side effects reported with Daklinza in combination with sofosbuvir with or without ribavirin are fatigue (tiredness), nausea (feeling sick) and headache. 
Najpogostejši neželeni učinki, o katerih so poročali pri uporabi zdravila Daklinza v kombinaciji s sofosbuvirjem in ribavirinom ali brez njega, so utrujenost, navzeja (slabost) in glavobol.
For more information on the medicines that should not be taken with Daklinza, see the package leaflet. 
Za več informacij o zdravilih, ki se ne smejo jemati sočasno z zdravilom Daklinza, glejte
How does Daklinza work? 
Kako zdravilo Daklinza deluje?
The Agency therefore concluded that the benefits of Daklinza outweigh its risks and recommended that 
Agencija je zato zaključila, da so koristi zdravila Daklinza večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
Daklinza can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with chronic hepatitis C. 
Predpisovanje in izdaja zdravila Daklinza je le na recept, zdravljenje pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s kroničnim hepatitisom C.
The combination of medicines to use and the duration of treatment will depend on the genotype of hepatitis C virus the patient is infected with and the nature of the liver problem, for example liver cirrhosis (scarring) or the liver not working well enough. 
Uporabljena kombinacija zdravil in trajanje zdravljenja bosta odvisna od tega, s katerim genotipom virusa hepatitisa C je bolnik okužen, in vrste njegovih težav z jetri (ali gre na primer za cirozo (brazgotinjenje) jeter ali njihovo nepravilno delovanje).
The active substance in Daklinza, daclatasvir, blocks the action of a protein in the hepatitis C virus called ‘NS5A', which is essential for the virus to multiply. 
Zdravilna učinkovina zdravila Daklinza, daklatasvir, zavira delovanje beljakovine v virusu hepatitisa C, imenovane „NS5A“, ki ima ključno vlogo pri razmnoževanju virusa.
It contains the active substance daclatasvir. 
Zdravilo vsebuje zdravilno učinkovino daklatasvir.
The European Commission granted a marketing authorisation valid throughout the European Union for Daklinza on 22 August 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Daklinza, veljavno po vsej Evropski uniji, izdala